Preparation of polymeric nanoparticles of cyclosporin A using infrared pulsed laser

International Journal of Pharmaceutics

Volumn 414, Issue 1-2, 2011, Pages 244-250

  Takebe, Gen ^a   Takagi, Tokio ^a   Suzuki, Masumi ^a   Hiramatsu, Mitsuo ^a  

^a CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Cyclosporin A; Laser technology; Polymeric nanoparticles; Polyvinyl pyrrolidone

Indexed keywords

CYCLOSPORIN A; DODECYL SULFATE SODIUM; INTERLEUKIN 2; NANOPARTICLE; POVIDONE;

ARTICLE; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; INFRARED RADIATION; LASER; NANOPHARMACEUTICS; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL;

CYCLOSPORINE; CYTOKINES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; JURKAT CELLS; LASER THERAPY, LOW-LEVEL; NANOPARTICLES; PARTICLE SIZE; POLYMERS; SOLUBILITY;

EID: 79959693295     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.05.012     Document Type: Article

References (36)

1. M.J. Akers Excipient-drug interactions in parenteral formulations J. Pharm. Sci. 91 2002 2283 2300 (Pubitemid 35231192)
2. H.M. Aliabadi, A. Mahmud, A.D. Sharifabadi, and A. Lavasanifar Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A J. Control. Release 104 2005 301 311 (Pubitemid 40724931)
3. L. Andrus, and K.J. Lafferty Inhibition of T-cell activity by cyclosporin A Scand. J. Immunol. 15 1981 449 458 (Pubitemid 12124743)
4. T. Asahi, T. Sugiyama, and H. Masuhara Laser fabrication and spectroscopy of organic nanoparticles Acc. Chem. Res. 41 2008 1790 1798
5. B.H.L. Böhm, and R.H. Müller Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs Pharm. Sci. Technolo. Today 2 1999 336 339 (Pubitemid 29378538)
6. D.J. Cohen, R. Loertscher, M.F. Rubin, N.L. Tilney, C.B. Carpenter, and T.B. Strom Cyclosporine: a new immunosuppressive agent for organ transplantation Ann. Intern. Med. 101 1984 667 682 (Pubitemid 15223313)
7. D.Q. Craig The mechanisms of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 231 2002 131 144 (Pubitemid 34033673)
8. J. Dai, T. Nagai, X. Wang, T. Zhang, M. Meng, and Q. Zhang pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A Int. J. Pharm. 280 2004 229 240 (Pubitemid 38950919)
9. C.J. Dunn, A.J. Wagstaff, C.M. Perry, G.L. Plosker, and K.L. Goa Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation Drugs 61 2001 1957 2016
10. M.H. El-Shabouri Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A Int. J. Pharm. 249 2002 101 108 (Pubitemid 35333436)
11. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598 (Pubitemid 32778603)
12. R.J. Hintz, and K.C. Johnson The effect of particle size distribution on dissolution rate and oral absorption Int. J. Pharm. 51 1989 9 17 (Pubitemid 19087827)
13. K. Itoh, A. Pongpeerapat, Y. Tozuka, T. Oguchi, and K. Yamamoto Nanoparticle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS Chem. Pharm. Bull. (Tokyo) 51 2003 171 174 (Pubitemid 41701987)
14. C.M. Keck Particle size analysis of nanocrystals: improved analysis method Int. J. Pharm. 390 2010 3 12
15. J.E. Kipp The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs Int. J. Pharm. 284 2004 109 122 (Pubitemid 39349144)
16. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug. Discov. 3 2004 711 715 (Pubitemid 39173511)
17. N. Kondo, T. Iwao, H. Masuda, K. Yamanouchi, Y. Ishihara, N. Yamada, T. Haga, Y. Ogawa, and K. Yokoyama Improved oral absorption of a poorly water-soluble drug HO-221, by wet-bead milling producing particles in submicron region Chem. Pharm. Bull. (Tokyo) 41 1993 737 740 (Pubitemid 23166149)
18. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249 (Pubitemid 32239479)
19. B. Manger, K.J. Hardy, A. Weiss, and J.D. Stobo Differential effect of cyclosporin A on activation signaling in human T cell lines J. Clin. Invest. 77 1986 1501 1506 (Pubitemid 16047094)
20. W. Mehnert, and K. Mäder Solid lipid nanoparticles: production, characterization and applications Adv. Drug. Deliv. Rev. 47 2001 165 196 (Pubitemid 32324113)
21. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 18 2003 113 120 (Pubitemid 36184748)
22. K. Miyake, F. Hirayama, and K. Uekama Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution J. Pharm. Sci. 88 1999 39 45 (Pubitemid 29037366)
23. E.A. Mueller, J.M. Kovarik, J.B. van Bree, W. Tetzloff, J. Grevel, and K. Kutz Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation Pharm. Res. 11 1994 301 304 (Pubitemid 24076228)
24. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170 (Pubitemid 39237077)
25. R.H. Müller, S. Runge, V. Ravelli, W. Mehnert, A.F. Thunemann, and E.B. Souto Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals Int. J. Pharm. 317 2006 82 89 (Pubitemid 43866342)
26. S. Nagare, and M. Senna Indomethacin nanoparticles directly deposited on the fluidized particulate excipient by pulsed laser deposition J. Nanopart. Res. 8 2004 37 42
27. S. Nagare, J. Sagawa, and M. Senna Chemical and structural properties of drug-protein nanocomposites prepared by pulsed laser deposition from conjugated targets J. Nanopart. Res. 6 2006 589 593
28. J.E. Patterson, M.B. James, A.H. Forster, R.W. Lancaster, J.M. Butler, and T. Rades Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling Int. J. Pharm. 336 2007 22 34 (Pubitemid 46551551)
29. B.A. Perrino, A.J. Wilson, P. Ellison, and L.H. Clapp Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the alpha or beta catalytic subunit Eur. J. Biochem. 269 2002 3540 3548 (Pubitemid 34988998)
30. R.A. Prentis, Y. Lis, and S.R. Walker Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985) Br. J. Clin. Pharmacol. 25 1988 387 396
31. M. Rawat, D. Singh, S. Saraf, and S. Saraf Nanocarriers: promising vehicle for bioactive drugs Biol. Pharm. Bull. 29 2006 1790 1798 (Pubitemid 44338396)
32. A.T. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
33. A.W. Thomson, and G.H. Neild Cyclosporin: use outside transplantation Br. Med. J. 302 1991 4 5
34. X.Q. Wang, J.D. Dai, Z. Chen, T. Zhang, G.M. Xia, T. Nagai, and Q. Zhang Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration J. Control. Release 97 2004 421 429 (Pubitemid 38802944)
35. L. Yu Amorphous pharmaceutical solids: preparation, characterization and stabilization Adv. Drug. Deliv. Rev. 48 2001 27 42 (Pubitemid 32454482)
36. H. Zhang, J. Bei, and S. Wang Multi-morphological biodegradable PLGE nanoparticles and their drug release behavior Biomaterials 30 2009 100 107